SCHEMBL41129

SCHEMBL41129

COC(=O)c1cnc(N)c(N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 3/20 0.51
ATM Q13315 2/20 0.51
GLA P06280 2/20 0.51
MAPT P10636 2/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
PDGFRB P09619 6/20 0.50
KDR P35968 6/20 0.50
MAPK1 P28482 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.46
PSMD14 O00487 1/20 0.44
USP2 O75604 1/20 0.44
CSF1R P07333 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31705858 1.00 KDM4E (0.51) KDM4EALDH1A1GAAATMGLA
SCHEMBL31309479 0.84 ATM (0.51) KDM4EALDH1A1GAAATMGLA
SCHEMBL12488317 0.84 ATM (0.51) KDM4EALDH1A1GAAATMGLA
SCHEMBL19029214 0.84 KDM4E (0.50) KDM4EALDH1A1GAAATMGLA
SCHEMBL16421752 0.84 ATM (0.51) KDM4EALDH1A1GAAATMGLA
SCHEMBL14997361 0.84 KDM4E (0.53) KDM4EALDH1A1GAAATMGLA
SCHEMBL27818191 0.84 KDM4E (0.50) KDM4EALDH1A1GAAATMGLA
SCHEMBL13209504 0.83 KDM4E (0.46) KDM4EALDH1A1GAAATMGLA
SCHEMBL5819835 0.82 KDM4E (0.49) KDM4EALDH1A1GAAATMGLA
SCHEMBL6749087 0.82 KDM4E (0.49) KDM4EALDH1A1GAAATMGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215593-A1 AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN HETERO LABS LIMITED (IN) 2025-10-16 WO claimed
WO-2025215593-A1 AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN HETERO LABS LIMITED (IN) 2025-10-16 WO disclosed
EP-4577537-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2025-07-02 EP disclosed
CN-120091998-A Substituted bicyclic rings as HSET inhibitors 默克专利股份公司 2025-06-03 CN disclosed
WO-2024042007-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-02-29 WO disclosed
US-20220227762-A1 AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2022-07-21 US disclosed
CN-113891880-A Amide substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenase 百济神州有限公司 2022-01-04 CN disclosed
CN-108602812-B Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals 坎塞拉有限公司 2021-11-02 CN disclosed
EP-3394052-B1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY KANCERA AB (SE) 2021-07-28 EP disclosed
US-10654814-B2 Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity KANCERA AB (SE) 2020-05-19 US disclosed
EP-1073657-A1 IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION AstraZeneca AB (SE) 2001-02-07 EP disclosed
WO-2000026211-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2000-05-11 WO disclosed
WO-1999055706-A9 IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION ASTRA AB (SE) 2000-03-16 WO disclosed
WO-1999055706-A1 IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION ASTRAZENECA AB (SE) 1999-11-04 WO disclosed
US-4920129-A Anti-ulcerative imidazopyridine compounds FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-04-24 US disclosed
US-4880815-A GASTRIC JUICE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-11-14 US disclosed
CN-1033628-A Imidazopyridine compound and preparation method thereof FUJISAWA PHARMACEUTIAL CO LTD (JP) 1989-07-05 CN disclosed
EP-0308917-A2 Imidazopyridine compound, a process for preparation thereof and pharmaceutical compositions comprising them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-03-29 EP disclosed
US-4738970-A Benzimidazolyl-thio-tetrahydroquinolines and anti-peptic ulcer compositions containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-04-19 US disclosed
EP-0187977-A1 Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654814-B2 Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity HDAC1, HDAC11, HDAC10 KDM4E 1411/4885ALDH1A1 1264/4885GAA 255/4885
US-20220227762-A1 AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES IDO1, IDO2, AADAC KDM4E 491/4885ALDH1A1 604/4885GAA 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.